Genpharmasec
- Market cap
- ₹ 55 Cr.
- P/E
- 83.8x
- P/B
- 0.85x
- 52-week range
- 0.75 – 1.8
- ROE
- 2%
- ROCE
- 3%
- Dividend yield
- 0%
- Debt / equity
- 0.53
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Genpharmasec Limited is an India-based company, which is engaged in the distribution of diagnostic pharma equipment and trading of securities. The Company’s segments include Pharmaceuticals, Trading in Securities, and Laboratory Testing. The Trading in Securities segment invests in the secondary securities market. The Company holds rights to the distribution of equipment, such as i-STAT Analyzers and its Cartridges, manufactured by Abbott Point of Care, USA, all over India. The i-STAT Analyzer is a blood analyzer used in Intensive Care Units (ICUs) of hospitals and provides test results in approximately 10 minutes. The Company’s wholly owned subsidiary includes M/s. Clinigenome India Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Genpharmasec against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)83.8 against a typical 28.5: pricier than most peers (1st = cheapest).141st of 186
- Sales growth+312.9% against a typical −2.4% from a year earlier.7th of 143
- Profit growth−113.9% against a typical −13.1% from a year earlier.102nd of 124
- Share price, 3 months−4.9% against a typical −4.9%.84th of 169
- Size₹ 54.9 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).67th of 183
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 6 | 10 | 5 | 6 | 8 | 14 | 12 | 33 | 40 | 55 | 50 |
| Expenses | 8 | 6 | 10 | 5 | 6 | 8 | 15 | 11 | 33 | 41 | 53 | 49 |
| Operating Profit | −0 | 0 | −0 | 0 | 0 | 1 | −1 | 1 | −0 | −1 | 2 | 1 |
| OPM % | −0.4% | 0.2% | −0.1% | 3.9% | 2.2% | 8.5% | −7.1% | 7.8% | −1.4% | −3.1% | 3.6% | 1.9% |
| Other Income | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 1 | 1 | 1 | −0 | 1 | −1 | −1 | 2 | 0 |
| Tax % | 80% | −100% | 345.5% | 35.3% | −39.2% | 40.2% | −37.2% | 2.4% | 48.1% | −37.3% | 27% | 165.4% |
| Net Profit | 0 | 0 | −0 | 0 | 1 | 1 | −0 | 1 | −1 | −1 | 1 | −0 |
| EPS in Rs | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0.02 | −0.02 | −0.01 | 0.03 | 0 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 76%
- TTM
- 338%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 13%
- TTM
- −111%
- 10 Years
- 20%
- 5 Years
- −27%
- 3 Years
- −21%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Genpharmasec | ₹ 0.98 | ₹ 55 Cr. | 83.8x | 0.9x | 2% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Sohan Chaturvedi
- Chief Financial Officer, Whole Time Director
- Hardik Makwana
- Chief Compliance Officer, Whole Time Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.